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When and How Should We Lyse?*



































lWith the advent of the Starr-Edwards mechanical
mitral and aortic valves in the 1960s, the surgical era
of the treatment of cardiac valvular disease began in
earnest. Although considered definitive, valve re-
placement surgery effectively represents an ex-
change of the pathophysiology of severe valvular
dysfunction for the diseases and complications as-
sociated with prosthetic valves. These include severe
paravalvular leak, endocarditis, severe hemolysis,
valvular dehiscence, valve failure, and prosthetic
valve thrombosis (PVT).
See page 206
The current rate of PVT is estimated to be
between 0.03% and 0.13% per patient-year depend-
ing on the antithrombotic regimen used and the
adherence to therapy (1). The rarity of PVT, its
broad spectrum of clinical presentation, and the
occasional difficulty in differentiating thrombosis
from pannus formation has presented numerous
challenges in its diagnosis, management, and sys-
tematic study. Previous studies of therapies for PVT
have lacked uniformity in definitions of obstruction,
treatment success, and diagnostic techniques. Study
designs of key reports in the field have included case
series (2–4) and retrospective cohorts (5) and have
often enrolled patients with both right- and left-
sided valvular obstruction. Finally, studies compar-
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zed and thus marked by selection bias (6,7).
As a result, comparing fibrinolytics and fibrino-
ysis with surgery has been difficult. In the absence
f randomized clinical trial data to guide therapeu-
ic strategies for PVT, current guidelines rely on
imited data and expert opinion. This has led to a
ariety of recommendations with regard to the role
f surgical valve replacement and systemic fibrino-
ysis with no class I recommendations being given
8–10). Surgery is recommended as first-line ther-
py by the European Society of Cardiology regard-
ess of clinical status, whereas the Society of Heart
alve Disease has recommended fibrinolysis as
rst-line therapy in all cases of PVT in the absence
f a contraindication (11). The American College
f Chest Physicians (10) recommends thrombolysis
s first-line therapy for thrombi 0.8 cm2, and the
oint American Heart Association and American
ollege of Cardiology guidelines suggest thrombol-
sis only for stable patients with PVT and incom-
lete obstruction (9).
It is with this background that the report by
zkan et al. (12) on the TROIA study in this issue
f iJACC should be considered. The TROIA
Comparison of Different TRansesophageal Echo-
ardiography Guided thrOmbolytic Regimens for
rosthetIc vAlve Thrombosis) study evaluated a strat-
gy of transesophageal echocardiography (TEE)–guided
brinolysis with rapid infusion of streptokinase
Group I) versus slow infusion of streptokinase
Group II) versus full-dose tissue plasminogen ac-
ivator (t-PA) (100 mg) (Group III) versus half
ose (50 mg) slow infusion of t-PA (Group IV)
ersus low dose (25 mg) slow infusion of t-PA
Group V). The investigators should be congratu-
ated for performing a single-center, prospective
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218patients with 220 episodes of PVT from 1993 to
2009, with a key feature of the study being that
enrollment in the study arms was nonrandomized
and occurred sequentially during the study period.
The pre-specified efficacy endpoint was thrombo-
lytic success, defined as the absence of fatal or
nonfatal complications and at least 1 of the follow-
ing criteria: 1) resolution of Doppler gradient and
decreased valve area; 2) clinical improvement in
symptoms; and 3) reduction 75% of the area or
major diameter of the thrombus. The pre-specified
safety endpoints were: 1) all-cause in-hospital mor-
tality; 2) nonfatal major complications (ischemic
stroke, intracranial hemorrhage, embolism, bleed-
ing requiring transfusion); and 3) nonfatal minor
complications (bleeding without the need for trans-
fusion and transient ischemic attack).
The investigators report successful thrombolysis
in 83.2% of cases without a significant difference
between thrombolytic protocols (68.8%, 85.4%,
75.0%, 81.5%, and 85.5%, respectively; p  0.46).
In multivariate analysis, only a longer time interval
since surgery (odds ratio: 1.025; 95% confidence
interval: 1.012 to 1.039; p  0.001), and not poor
New York Heart Association functional class, po-
sition of the thrombosed valve, bileaflet versus
monoleaflet valve, mobility of the thrombus, sub-
optimal international normalized ratio on admis-
sion, or previous aspirin use, was predictive of
fibrinolysis failure.
Importantly, the investigators went on to exam-
ine complications and report an overall complica-
tion rate of 18.6%, including death (14.6%), and
nonfatal major (41.5%) and minor (43.9%) compli-
cations. Analysis of complication rates by group
showed a statistically lower combined complication
rate in Group V (10.5%) compared with all other
groups (37.5%, 24.4%, 33.3%, 29.6%, and 10.5%,
respectively; p  0.01 for Group I vs. Group V,
.03 for Group II vs. Group V, 0.04 for Group III
s. Group V, and 0.03 for Group IV vs. Group V).
xamination of the components of this composite
ndpoint suggests that the lower complication rate
n Group V was driven primarily by a lower mor-
ality rate compared with Groups I (12.5%) and III
16.7%) and lower nonfatal complication rate com-
ared with Groups II (12.12%) and IV (11.1%).
ultivariate analysis revealed only a history of
ransient ischemic attack/stroke and non-Group V
tatus, but not atrial fibrillation, obstructive throm-
us, large thrombus, or poor functional capacity as
redictors of complications.Although hampered by possible bias and con-
founding due to its single-center, nonrandomized,
and sequential design, the present study neverthe-
less represents the largest of its kind to date and
provides important data regarding the relative effi-
cacy of multiple thrombolytic regimens in the
setting of PVT. Whereas previous studies separately
evaluated a variety of thrombolytic agents and
regimens, including streptokinase, urokinase, and
t-PA, few used either direct or indirect comparison
to attempt to identify differences in efficacy and
safety based on dosing regimens or varying throm-
bolytic agents (3,13). As a result, fibrinolytic dosing
for thrombolysis in PVT has largely been borrowed
from the pulmonary embolism and myocardial in-
farction literature without critical appraisal. In fact,
whereas dosing guidelines for fibrinolysis in pulmo-
nary embolism emphasize that shorter infusion
times achieve more rapid clot lysis with lower
bleeding rates (14), the results of the present study
suggest that lower dose, TEE-guided, repeated,
slow administration of a fibrinolytic agent may be
equally efficacious with fewer complications.
Given the improvement in safety and preserved
efficacy associated with their protocol, Özkan et al.
(12) suggest that guidelines regarding the treatment
of PVT may need to be updated to reflect the utility
of fibrinolysis for all patients, even those who are
critically ill. Although administration of slow, low-
dose t-PA appears to compare favorably with pre-
vious reports of fibrinolytic and surgical treatment
of PVT, because the TROIA study did not include
a surgical therapy arm, these data should be inter-
preted as pilot data forming the basis for a clinical
trial rather than as definitive proof of the equiva-
lence or superiority of fibrinolysis over surgery in
PVT. As such, they are unlikely to significantly
change the recommendations of the individual
guideline agencies, which have already made widely
differing interpretations of the available data.
The recently initiated SAFE-PVT (Surgery Ver-
sus Fibrinolytic Therapy for Left-sided Prosthetic
Heart Valve Thrombosis) study (NCT01641549)
will randomize 150 patients at a single center in
India to surgical valve replacement or thrombec-
tomy versus first-line therapy with fibrinolysis with
streptokinase or an alternative fibrinolytic agent.
Results of this trial are currently expected in 2017
and will include a primary endpoint of in-hospital
complete clinical response in the absence of stroke,
bleeding, or systemic embolism. The secondary
endpoints will be in-hospital and 1 year stroke,
bleeding, and systemic embolism.
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219The findings of this study will be crucial in
informing guidelines on the treatment of PVT as
the data will begin to address several of the out-
standing questions within the PVT therapeutic
literature: 1) what are the success and complication
rates of contemporary, unselected patients under-
going left-sided surgical thrombectomy or valve
replacement for PVT? 2) Is there a difference
between fibrinolytic agents with regard to effective-
ness and safety in contemporaneously enrolled sub-6. Lengyel M, Vandor L. The role of
thrombolysis in the management of
1
Gutterman DD, S
Executive summarof patients undergoing surgical or fibrinolytic ther-
apy for PVT? Until then, if fibrinolysis is to be used
for PVT, the data from the current study suggest
that lower dose, TEE-guided repeated, slow ad-
ministration of a fibrinolytic agent may be the best
choice for efficacy and safety.
Reprint requests and correspondence: Dr. Sreekanth Vemu-
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